AIRDOC-B (02251) stock surged 5.57% in Friday's intraday trading following the release of its impressive interim results for the first half of 2025. The company reported a significant turnaround, swinging from a loss to a profit, which has evidently boosted investor confidence.

According to the interim report, AIRDOC-B achieved a profit of RMB 443,000 for the six months ended June 30, 2025, compared to a loss of RMB 81.488 million in the same period last year. This remarkable turnaround was accompanied by solid financial performance, with revenue reaching RMB 83.713 million and gross profit of RMB 64.103 million, representing a year-on-year increase of 13.53%.

The company's growth was driven by expansion across multiple segments. AIRDOC-B reported a 20.7% year-on-year increase in active service points for retinal detection AI products, rising from 5,950 to 7,180. The usage of myopia prevention and control AI products surged by 68.1% year-on-year, reaching 2.812 million times. Additionally, the company successfully launched a new generation physiological stress resistance testing device, further diversifying its product portfolio. These developments, combined with the company's return to profitability, appear to have fueled the stock's significant upward movement in today's trading session.